- Home
- BDTX vs ACHV Comparison
BDTX vs ACHV Comparison
Compare BDTX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- ACHV
- Stock Information
- Founded
- BDTX 2014
- ACHV N/A
- Country
- BDTX United States
- ACHV Canada
- Employees
- BDTX N/A
- ACHV N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BDTX Health Care
- ACHV Health Care
- Exchange
- BDTX Nasdaq
- ACHV Nasdaq
- Market Cap
- BDTX 144.9M
- ACHV 149.6M
- IPO Year
- BDTX 2020
- ACHV N/A
- Fundamental
- Price
- BDTX $2.48
- ACHV $4.18
- Analyst Decision
- BDTX Strong Buy
- ACHV Strong Buy
- Analyst Count
- BDTX 4
- ACHV 5
- Target Price
- BDTX $15.50
- ACHV $14.80
- AVG Volume (30 Days)
- BDTX 476.4K
- ACHV 113.3K
- Earning Date
- BDTX 11-05-2024
- ACHV 11-07-2024
- Dividend Yield
- BDTX N/A
- ACHV N/A
- EPS Growth
- BDTX N/A
- ACHV N/A
- EPS
- BDTX N/A
- ACHV N/A
- Revenue
- BDTX N/A
- ACHV N/A
- Revenue This Year
- BDTX N/A
- ACHV N/A
- Revenue Next Year
- BDTX N/A
- ACHV N/A
- P/E Ratio
- BDTX N/A
- ACHV N/A
- Revenue Growth
- BDTX N/A
- ACHV N/A
- 52 Week Low
- BDTX $2.31
- ACHV $3.20
- 52 Week High
- BDTX $7.66
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- BDTX 43.96
- ACHV 38.91
- Support Level
- BDTX $2.43
- ACHV $4.02
- Resistance Level
- BDTX $2.66
- ACHV $4.66
- Average True Range (ATR)
- BDTX 0.16
- ACHV 0.17
- MACD
- BDTX 0.05
- ACHV -0.02
- Stochastic Oscillator
- BDTX 48.81
- ACHV 23.44
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.